New
Johnson & Johnson Tops Q4 Eps Forecasts
Pharmaceuticals and medical devices manufacturer Johnson & Johnson (NYSE:JNJ) reported fourth-quarter 2024 results on Wednesday, Jan. 22, that topped analyst consensus estimates. Revenue of $22.5 billion came in just ahead of forecasts for $22.4 billion while adjusted earnings per share (EPS) of $2.04 also surpassed the $1.99 estimate.
Although sales surged in the Innovative Medicine and MedTech segments, patent expirations and regulatory challenges remain concerns. Overall, Johnson & Johnson had a strong quarter, continuing to expand its product pipeline and positioning itself well amid market fluctuations.
| Metric | Q4 2024 | Analysts' Estimate | Q4 2023 | Change (YOY) |
|---|---|---|---|---|
| Adjusted EPS | $2.04 | $1.99 | $2.29 | (10.9%) |
| Revenue | $22.5 billion | $22.4 billion | $21.4 billion | 5.3% |
| Net earnings | $3.43 billion | N/A | $4.13 billion | (17%) |
| Adjusted net earnings | $4.95 billion | N/A | $5.56 billion | (11.1%) |
Source: Johnson & Johnson. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year.
About Johnson & Johnson
Johnson & Johnson is a diversified healthcare giant that is broadly segmented into Innovative Medicine and MedTech. Its Innovative Medicine division covers pharmaceuticals focusing on areas like immunology and oncology, alongside MedTech engaging in medical devices like cardiovascular solutions. Success stems from robust product portfolios, continuous innovation, and a strategic focus on market relevance. Recent accomplishments include advancements through strategic acquisitions, like Abiomed, strengthening its cardiovascular offerings. Innovation remains core, seen in new products such as SPRAVATO for depression and the OTTAVA robotic system.
Johnson & Johnson recently concentrated on fostering innovations within its segments, maintaining competitive edges through continuous research and development (R&D) in emerging healthcare areas. Critical success factors for the company encompass driving revenue via impactful new product launches and preserving intellectual property against generic competition.
Quarter in Review: Financial and Operational Highlights
This quarter, sales in its Innovative Medicine segment grew by 4.4% year over year, led by products like Darzalex in oncology and Tremfya in immunology. However, Stelara's sales saw a decline amid mounting biosimilar competition. The MedTech segment realized 6.7% sales growth, spurred by breakthroughs in the cardiovascular sector through strategic acquisitions like Abiomed. Adjusted net earnings decreased 11.1% from $5.56 billion in Q4 2023 to $4.95 billion, highlighting ongoing challenges such as litigation related to talc products that weighed heavily on adjusted earnings.
Operational challenges include looming patent expirations for key products like Stelara, with potential revenue impacts from increased biosimilar competition. Legal complexities, especially the talc-related litigations, have persisted, affecting earnings. Additionally, patent protection and regulatory hurdles continue to shape its strategic focus, prolonging the product lifecycle via innovation and partnerships.
The company reported dividend increase continuity, showcasing robust investor return strategies despite external pressures. A 5.3% year-over-year revenue growth accentuates its substantial market resilience amidst these challenges, driven by innovative products and strategic market expansions.
The Road Ahead for Johnson & Johnson
Johnson & Johnson management expects operational sales growth between 2.5% and 3.5% in 2025, indicating a strategic focus on consistent mid-point growth. Adjusted operational EPS for 2025 is projected to range between $10.75 and $10.95, reflecting management's confidence in its business strategies encompassing pipeline developments and market expansions.
Investors should monitor the impact of patent expirations and litigation proceedings on financial health. Growth across its crucial segments suggests a solid trajectory with continued investments in R&D and strategic collaborations enhancing product pipelines and operational efficiencies.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 894% — a market-crushing outperformance compared to 176% for the S&P 500.*
They just revealed what they believe are the 10 best stocks for investors to buy right now…
*Stock Advisor returns as of January 21, 2025
JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
